12th World Clinical Biomarkers and CDx Summit

The 12th World Clinical Biomarkers and CDx Summit returns at a crucial time for the entire precision and targeted drug development industry. Spurred on by a number of recent exciting biomarker-driven therapy and CDx approvals by the FDA, including Eli Lilly's Verzenio, J&J's Amivantamab and Takeda's Mobocertinib, the race to market is becoming ever fiercer to deliver the next-generation of safer and more effective therapies for defined patient populations.

Returning in-person for the first time in three years, hear the latest insights, case studies and technologies enhancing your predictive biomarker discovery, to support next generation CDx development, informed clinical decisions, regulatory approval and a robust go-to market strategy for a breakthrough therapy.

Across 2-days and 3 distinct tracks, this is your only end-to-end biomarker-driven and diagnostic enabled drug development summit, led by 70+ industry leaders triumphing and overcoming challenges to predictive biomarker development and commercialization.

You cannot afford to miss World CB and CDx 2022, as key industry stakeholders gather and leave no stone unturned to advance more life changing precision and targeted drugs to patients.

Speakers: Aaron Schetter, Senior Director, Regulatory Affairs, Companion Diagnostics, Daiichi Sankyo, Inc., Amy Gorman, Director, Global Commercial Strategy, Precision Medicine, Janssen, Antonio Chambers, Associate Director, Technical Diagnostic Testing Services, Eli Lilly and Company, Brian Baker, Senior Director, Regulatory Affairs (CDx), Regeneron, Christine Martersteck, Manager Diagnostic Development, Loxo Oncology at Lilly, Deepti Aurora-Garg, Executive Director, Companion Diagnostics | Vice President Companion Diagnostics,  Merck | Prometheus Biosciences, Dun Liang, Director, Regulatory Affairs, CDx, Loxo Oncology at Lilly, Heather Cohen, Director, Translational Sciences and Diagnostics, Bicycle Therapeutics, Hilary Gee Goeckner, Senior State and Local Campaigns Manager, Access to Care, American Cancer Society Cancer Action Network, James Hewitt, IVD Product Expert, TÜV SÜD, Jason Baum, Vice President, Translational Medicine, Leap Therapeutics, Javier Perez, Director, Precision Medicine, Companion Diagnostics, Regeneron, Jeffrey Siegel, Office Director, Office of Drug Evaluation Sciences, OND, CDER, U.S. Food and Drug Administration, Jie Cheng, Senior Director, Statistical and Quantitative Sciences, Takeda Pharmaceutical Company, John Yi, Director, Translational Medicine, G1 Therapeutics, Kaska Kowanetz, Director, Global Regulatory Lead, Pfizer, Lakshman Ramamurthy, Head of Global Regulatory Affairs, Precision Medicine and Digital Health, GlaxoSmithKline, Lindsay Darling, Associate Director, Companion Diagnostics Portfolio Management and Operations, Regeneron, Maureen Lane, Vice President, Clinical Science, Curis Inc., Meijuan Li, Vice President, Head of Biostatistics, Oncology Group, Eisai, Melinda Day, Associate Director, Translational Clinical Development, Kronos Bio, Michael Lahn, Chief Executive Officer, iOnctura, Minghao Song, Director, Precision Medicine Lead, AstraZeneca, Neeraj Adya, Head of CDx, Genmab, Pamela Ebrahimi, Deputy Branch Chief, Molecular Genetics Branch, CDRH, U.S. Food and Drug Administration, Qing Li, Head of Clinical Biomarker and CDx Strategy, H3 Biomedicine, Sarah Hersey, Vice President, Precision Medicine, Bristol Myers Squibb, Satya Saxena, Director, Global Proteomics, Clinical Pharmacology and Translational Medicine, Neurology Business Group, Eisai, Shirin Khambata Ford, Vice President, Head Companion Diagnostics, Global Companion Diagnostics, Global Oncology R&D, Daiichi Sankyo, Si Tuen-Lee Hoeflich, Director, Scholar Rock, Sid Mathur, Regulatory Affairs Executive Director, Companion Diagnostics, Merck, Silva Krause, Senior Director, Clinical Biomarkers, Vertex Pharmaceuticals, Srinivas Venkatram, Director, CDx Strategy, AbbVie, Steve Anderson, Consultant, Precision Medicine and Oncology, Susanne Rhoades, Senior Director, Diagnostic Development, Loxo Oncology at Lilly, Victoria Rimkunas, Senior Director, Head of Translational Medicine, Repare Therapeutics, Wen-Chi Chou, Prinical Computational Biologist, Clinical Development Predictive Sciences (Oncology), Bristol Myers Squibb, Wenora Johnson, Research and Patient Advocate, Zhen Su, Chief Executive Officer, Marengo Therapeutics

Others Details

Brochure: https://go.evvnt.com/1145208-3?pid=6581